Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
SANOFI INDIA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SANOFI INDIA Dec-22 |
TEVA PHARMA Dec-13 |
SANOFI INDIA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 7,939 | 3,459 | - | |
Low | Rs | 5,454 | 3,005 | - | |
Sales per share (Unadj.) | Rs | 1,202.8 | 1,985.4 | - | |
Earnings per share (Unadj.) | Rs | 269.5 | 124.0 | - | |
Cash flow per share (Unadj.) | Rs | 287.7 | 284.5 | - | |
Dividends per share (Unadj.) | Rs | 570.00 | 108.57 | - | |
Avg Dividend yield | % | 8.5 | 3.4 | 253.4% | |
Book value per share (Unadj.) | Rs | 527.0 | 2,205.4 | - | |
Shares outstanding (eoy) | m | 23.03 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.6 | 1.6 | 342.0% | |
Avg P/E ratio | x | 24.9 | 26.1 | 95.4% | |
P/CF ratio (eoy) | x | 23.3 | 11.4 | 204.9% | |
Price / Book Value ratio | x | 12.7 | 1.5 | 867.1% | |
Dividend payout | % | 211.5 | 87.5 | 241.6% | |
Avg Mkt Cap | Rs m | 154,224 | 2,741,007 | 5.6% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 4,059 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,459.7 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,340.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 27,701 | 1,683,624 | 1.6% | |
Other income | Rs m | 730 | 0 | - | |
Total revenues | Rs m | 28,431 | 1,683,624 | 1.7% | |
Gross profit | Rs m | 8,349 | 461,061 | 1.8% | |
Depreciation | Rs m | 419 | 136,089 | 0.3% | |
Interest | Rs m | 17 | 33,069 | 0.1% | |
Profit before tax | Rs m | 8,643 | 291,903 | 3.0% | |
Minority Interest | Rs m | 0 | 1,326 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -191,619 | -0.0% | |
Tax | Rs m | 2,437 | -3,564 | -68.4% | |
Profit after tax | Rs m | 6,206 | 105,175 | 5.9% | |
Gross profit margin | % | 30.1 | 27.4 | 110.1% | |
Effective tax rate | % | 28.2 | -1.2 | -2,309.5% | |
Net profit margin | % | 22.4 | 6.2 | 358.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 36,121 | 1,137,114 | 3.2% | |
Current liabilities | Rs m | 27,425 | 991,659 | 2.8% | |
Net working cap to sales | % | 31.4 | 8.6 | 363.4% | |
Current ratio | x | 1.3 | 1.1 | 114.9% | |
Inventory Days | Days | 117 | 91 | 128.5% | |
Debtors Days | Days | 17 | 96 | 17.7% | |
Net fixed assets | Rs m | 12,148 | 549,909 | 2.2% | |
Share capital | Rs m | 230 | 4,144 | 5.6% | |
Net worth | Rs m | 12,136 | 1,870,187 | 0.6% | |
Long term debt | Rs m | 0 | 860,875 | 0.0% | |
Total assets | Rs m | 48,279 | 3,847,621 | 1.3% | |
Interest coverage | x | 509.4 | 9.8 | 5,183.8% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.4 | 131.1% | |
Return on assets | % | 12.9 | 3.6 | 358.7% | |
Return on equity | % | 51.1 | 5.6 | 909.3% | |
Return on capital | % | 71.4 | 4.9 | 1,447.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,987 | 268,283 | 1.5% | |
From Investments | Rs m | 6,509 | -95,063 | -6.8% | |
From Financial Activity | Rs m | -15,827 | -321,823 | 4.9% | |
Net Cashflow | Rs m | -5,331 | -148,604 | 3.6% |
Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare SANOFI INDIA With: SYSCHEM (I). TRIDENT LIFELINE SHUKRA PHARMA ZENITH DRUGS LTD. BAL PHARMA
Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.